1) Vinjamur, D. S.; Bauer, D. E.; Orkin, S. H. Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies. Br. J. Haematol. 2018, 180, 630–643.
2) Wilber, A.; Nienhuis, A. W.; Persons, D. A. Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood 2011, 117, 3945–3953.
3) Forget, B. G.; Bunn, H. F. Classification of the disorders of hemoglobin. Cold Spring Harbor Persp. Med. 2013, 3, a011684.
4) Musallam, K. M.; Taher, A. T.; Rachmilewitz, E. A. beta-thalassemia intermedia: a clinical perspective. Cold Spring Harbor Persp. Med. 2012, 2, a013482.
5) Weatherall, D. J. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010, 115, 4331–4336.
6) Lettre, G.; Bauer, D. E. Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies. The Lancet 2016, 387, 2554−2564.
7) Shaukat, I.; Paudel, A.; Yassin, S.; Höti, N.; Mustafa, S. Blessing in disguise; a case of Hereditary Persistence of Fetal Hemoglobin. J. Community Hosp. Intern. Med. Perspect. 2018, 8, 380–381.
8) Lanzkron, S.; Strouse, J. J.; Wilson, R.; Beach, M. C.; Haywood, C.; Park, H. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann. Intern. Med. 2008, 148, 939–955.
9) Borgna-Pignatti, C. The life of patients with thalassemia major. Haematologica. 2010, 95, 345– 348.
10) Niihara, Y.; Miller, S. T.; Kanter, J.; Lanzkron, S.; Smith, W. R.; Hsu, L. L.; Gordeuk, V. R.; Viswanathan, K.; Sarnaik, S.; Osunkwo, I.; Guillaume, E.; Sadanandan, S.; Sieger, L.; Lasky, J. L.; Panosyan, E. H.; Blake, O. A.; New, T. N.; Bellevue, R.; Tran, L. T.; Razon, R. L.; Stark, C. W.; Neumayr, L. D.; Vichinsky, E. P. A phase 3 trial of l-glutamine in sickle cell disease. N. Engl. J. Med. 2018, 379, 226−235.
11) Ataga, K. I.; Kutlar, A.; Kanter, J.; Liles, D.; Cancado, R.; Friedrisch, J.; Guthrie, T. H.; Knight - Madden, J.; Alvarez, O. A.; Gordeuk, V. R.; Gualandro, S.; Colella, M. P.; Smith, W. R.; Rollins, S. A.; Stocker, J. W.; Rother, R. P. Crizanlizumab for the prevention of pain crises in sickle cell disease. N. Engl. J. Med. 2017, 376, 429−439.
12) Vichinsky, E.; Hoppe, C. C.; Ataga, K. I.; Ware, R. E.; Nduba, V.; El-Beshlawy, A.; Hassab, H.; Achebe, M. M.; Alkindi, S.; Brown, R. C.; Diuguid, D. L.; Telfer, P.; Tsitsikas, D. A.; Elghandour, A.; Gordeuk, V. R.; Kanter, J.; Abboud, M. R.; Lehrer-Graiwer, J.; Tonda, M.; Intondi, A.; Tong, B.; Howard, J. A phase 3 randomized trial of voxelotor in sickle cell disease. N. Engl. J. Med. 2019, 381, 509−519.
13) Paikari, A.; Sheehan, V. A. Fetal Haemoglobin Induction in Sickle Cell Disease. Br. J. Haematol. 2018, 180, 189−200.
14) El-Beshlawy, A.; El-Ghamrawy, M. Recent trends in treatment of thalassemia. Blood Cells Mol. Dis. 2019, 76, 53−58.
15) Kurita, R.; Suda, N.; Sudo, K.; Miharada, K,; Hiroyama, T.; Miyoshi, H.; Tani, K.; Nakamura, Y. Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells. PLoS One. 2013, 8, e59890.
16) Mabaera, R.; Richardson, C. A.; Johnson, K.; Hsu, M.; Fiering, S.; Lowrey, C. H. Developmental- and differentiation-specific patterns of human gamma- and beta-globin promoter DNA methylation. Blood 2007, 110, 1343−1352.
17) Jaulmes, S.; Dugué, J.; Agafonov, V.; Céolin, R.; Cense, J. M.; Lepage, F. Structure of N-(2, 6-dimethylphenyl)-5-methylisoxazole-3-carboxamide and molecular-orbital study of C-H...O bonded dimers. Acta Cryst. 1993. C49, 1007−1011.
18) Lipinski, C. A.; Lombardo, F.; Dominy, B. L.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 1997, 23, 3−25.
19) Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. J. Med. Chem. 2006, 49, 5029−5046.
20) Rivers, A.; Molokie, R.; Lavelle, D. A new target for fetal hemoglobin reactivation. Haematologica 2019, 104, 2325−2327.
21) Canver, M. C.; Orkin, S. H. Customizing the genome as therapy for the betahemoglobinopathies. Blood, 2016, 127, 2536−2345.
22) Lee, Y. T.; de Vasconcellos, J. F.; Yuan, J.; Byrnes, C.; Noh, S. J.; Meier, E. R. et al. LIN28Bmediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo. Blood 2013, 122, 1034−1041.
23) Masuda, T.; Wang, X.; Maeda, M.; Canver, M. C.; Sher, F.; Funnell, A. P. et al. Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science 2016, 351, 285−289.
24) Macari, E. R.; Schaeffer, E. K.; West, R. J.; Lowrey, C. H. Simvastatin and tbutylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cells. Blood 2013, 121, 830−839.
25) Liu, N.; Xu, S.; Yao, Q.; Zhu, Q.; Kai, Y.; Hsu, J. Y.; Sakon, P.; Pinello, L.; Yuan, G. C.; Bauer, D. E.; Orkin, S. H. Nature Genetics 2021, 53, 511–520.
26) Ngo, D. A.; teinberg, M. H. Genomic approaches to identifying targets for treating β hemoglobinopathies. BMC Med. Genomics, 2015, 8, 44.
27) Cashen, A. F.; Shah, A. K.; Todt, L.; Fisher, N.; DiPersio, J.; Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother. Pharmacol. 2008, 61, 759–766.
28) Steinberg, M. H.; McCarthy, W. F.; Castro, O.; Ballas, S. K.; Armstrong, F. D.; Smith, W. et al., The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am. J. Hematol. 2010, 85, 403–408.
29) Lavelle, D.; Chin, J.; Vaitkus, K,; Redkar, S.; Phiasivongsa, P.; Tang, C. et al. Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio Anubis. Am. J. Hematol. 2007, 82, 981–985.
30) Radchenko, D. S.; Pavlenko, S. O.; Grygorenko, O. O.; Volochnyuk, D. M.; Shishkina, S. V.; Shishkin, O. V.; Komarov, I. V. Cyclobutane-Derived Diamines: Synthesis and Molecular Structure. J. Org. Chem. 2010, 75, 5941–5952.
31) Burkhard, J. A.; Wagner, B.; Fischer, H.; Schuler, F.; Müller, K.; Carreira, E. M. Synthesis of azaspirocycles and their evaluation in drug discovery. Angew. Chem. Int. Ed. 2010, 49, 3524– 3527.
32) Boiteau, J. G.; Ouvry, G.; Arlabosse, J. M.; Astri, S. et al. Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis. Bioorg. Med. Chem. 2018, 26, 945–956.
33) Caldwell, R. D.; Qiu, H.; Askew, B. C.; Bender, A. T.; Brugger, N. et.al. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J. Med. Chem. 2019, 62, 7643–7655.
34) Zhang, X.; Sheng, X.; Shen, J.; Zhang, S. et al. Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor. ACS Med. Chem. Lett. 2020, 11, 1863–1868.
35) Gehling, V. S.; McGrath, J. P.; Duplessis, M. et al. Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors. ACS Med. Chem. Lett. 2020, 11, 1213–1220.
36) Swinney, D. C.; Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discov. 2011, 10, 507–519.
37) Moffat, J. G.; Vincent, F.; Lee, J. A.; Eder, J.; Prunotto, M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat. Rev. Drug Discov. 2017, 16 531–543.
38) Moffat, J. G.; Rudolph, J.; Bailey, D. Phenotypic screening in cancer drug discovery -past, present and future. Nat. Rev. Drug Discov. 2014, 13, 588–602.
39) Wolffe, A. P.; Matzke, M. A. Epigenetics:regulation throughrepression. Science 1999, 286, 481–486.
40) Suzuki, T. Development of next generation epigenetic drugs. 医学のあゆみ, 2015, 255, 654–658.
41) Xu, J.; Shao, Z.; Glass, K. et al. Combinatorial assembly of developmental stage-specific enhancers controls gene expression programs during human erythropoiesis. Dev. Cell 2012, 23, 796–811.
42) Ley, T. J.; DeSimone, J.; Anagnou, N. P. et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N. Engl. J. Med. 1982, 307, 1469–1475.
43) Bradner, J. E.; Mak, R.; Tanguturi, S. K. et al. Chemical genetic strategy identifi es histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc. Natl. Acad. Sci. USA 2010, 107, 12617–12622.
44) Tachibana, M.; Sugimoto, K.; Fukushima, T.; Shinkai, Y. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J. Biol. Chem. 2001, 276, 25309–25317.
45) Wang, Y. F.; Zhang, J.; Su, Y.; Shen, Y. Y.; Jiang, D. X.; Hou, Y. Y.; Geng, M. Y.; Ding, J.; Chen, Y. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Nat. Commun. 2017, 8, 274.
46) Huang, T.; Zhang, P.; Li, W.; Zhao, T.; Zhang, Z.; Chen, S.; Yang, Y.; Feng, Y.; Li, F.; Liu, X. S.; Zhang, L.; Jiang, G.; Zhang, F. G9A promotes tumor cell growth and invasion by silencing CASP1 in non-small-cell lung cancer cells. Cell Death Dis. 2017, 8, e2726.
47) Zhang, J.; Wang, Y.; Shen, Y.; He, P.; Ding, J.; Chen, Y.; G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1. Theranostics 2018, 8, 2884– 2895.
48) Krivega, I.; Byrnes, C.; de Vasconcellos, J. F.; Lee, Y. T.; Kaushal, M.; Dean, A.; Miller, J. L. Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR/γ-globin looping. Blood 2015, 126, 665−672.
49) Renneville, A.; Van Galen, P.; Canver, M. C.; McConkey, M.; Krill-Burger, J. M.; Dorfman, D. M.; Holson, E. B.; Bernstein, B. E.; Orkin, S. H.; Bauer, D. E.; Ebert, B. L. EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood 2015, 126, 1930−1939.
50) The Human Protein Atlas. https://www.proteinatlas.org/（2021 年 2 月 23 日）
51) Epizyme 社は EZM8266 を開発したが、毒物学研究の結果により前臨床試験を中止した。https://epizyme.gcs-web.com/news-releases/news-release-details/epizyme-announces- positive-pre-nda-meeting-tazemetostat（2021 年 2 月 23 日）
52) Cao, H.; Li, L.; Yang, D.; Zeng, L.; Yewei, X.; Yu, B.; Liao, G.; Chen, J. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents. Eur. J. Med. Chem. 2019, 179, 537–546.
53) Kubicek, S.; O'Sullivan, R. J.; August, E. M.; Hickey, E. R.; Zhang, Q.; Teodoro, M. L.; Rea, S.; Mechtler, K.; Kowalski, J. A.; Homon, C. A.; Kelly, T. A.; Jenuwein, T. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 2007, 25, 473–481.
54) Yuan, Y.; Wang, Q.; Paulk, J.; Kubicek, S.; Kemp, M. M.; Adams, D. J.; Shamji, A. F.; Wagner, P. K.; Schreiber, S. L. A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem. Biol. 2012, 7, 1152–1157.
55) Greiner, D.; Bonaldi, T.; Eskeland, R.; Roemer, E.; Imhof, A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 2005, 1, 143–145.
56) J. Zhang, Y.G. Zheng, SAM/SAH analogs as versatile tools for SAM-dependent methyltransferases. ACS Chem. Biol. 2016, 11, 583–597.
57) Vedadi, M.; Barsyte-Lovejoy, D.; Liu, F.; Rival-Gervier, S.; Allali-Hassani, A.; Labrie, V.; Wigle, T.J.; et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol. 2011, 7, 566–574.
58) Liu, F.; Barsyte-Lovejoy, D.; Allali-Hassani, A.; He, Y.; Herold, J. M.; Chen, X.; Yates, C. M.; Frye, S. V.; Brown, P. J.; Huang, J.; Vedadi, M.; Arrowsmith, C. H.; Jin, J. Optimization of cellular activity of G9a inhibitors 7 -aminoalkoxy-quinazolines. J. Med. Chem. 2011, 54, 6139– 6150.
59) Liu, D. F.; Barsyte-Lovejoy, D.; Li, F.; Xiong, Y.; Korboukh, V.; Huang, X. P.; Allali-Hassani, A.; Janzen, W. P.; Roth, P. L.; Frye, S. V.; Arrowsmith, C. H.; Brown, P. J.; Vedadi, M.; Jin, J. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J. Med. Chem. 2013, 56, 8931–8942.
60) Jose-Eneriz, S. E.; Agirre, X.; Rabal, O.; Vilas-Zornoza, A.; Sanchez-Arias, J. A.; Miranda, E.; Ugarte, A.; Roa, S.; Paiva, B.; Estella-Hermoso de Mendoza, A.; Alvarez, R. M.; Casares, N.; Segura, V. et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs with in vivo activity in hematological malignancies. Nat. Commun. 2017, 8, 15424.
61) Sweis, R. F.; Pliushchev, M.; Brown, P. J.; Guo, J.; Li, F.; Maag, D.; Petros, A. M.; Soni, N. B.; Tse, C.; Vedadi, M.; Michaelides, M. R.; Chiang, G. G.; Pappano, W. N. ACS Med Chem Lett. 2014, 5, 205–209.
62) 59th Annual Meeting & Exposition of the American Society of Hematology (ASH), Dec 9 –12, 2017, Reawakening of human fetal hemoglobin and an epigenetic path to the clinic for sickle cell disease and beta-thalassemia: identification of an orally-available, potent, and selective euchromatic histone lysine methyltransferase 1 and 2 (EHMT1/2) inhibitor. https://ashpublications.org/blood/article/130/Supplement%201/537/115843/ （2021 年 2 月 23日）
63) Emmerson, C. J.; William, D. K.; Alene, F. M. et al. Amine-substituted aryl or heteroaryl compounds as EHMT1 and EHMT2 inhibitors and their preparation. WO 2017/181177 A1, Oct. 19, 2017.
64) Moustakim, M.; Felce, S. L.; Zaarour, N.; Farnie, G.; McCann, F. E.; Brennan, P. E. Chapter Two-Target identification using chemical probes. Method Enzymol. 2018, 610, 27–58.
65) Campbell, J. E.; Duncan, K. W. Preparation of Substituted Fused Bi- or Tri-Heterocyclic Compounds as EHMT2 Inhibitors. WO 2018/064557, Apr. 5, 2018.
66) Rabal, O.; Sánchez-Arias, J. A.; José-Enériz, S. E.; Agirre, X.; de Miguel, I.; Garate, L.; Miranda, E.; Sáez, E.; Roa, S.; Martínez-Climent, J. A.; Liu, Y.; Wu, W.; Xu, M.; Prosper, F.; Oyarzabal, J. Detailed exploration around 4-aminoquinolines chemical space to navigate the lysine methyltransferase G9a and DNA methyltransferase biological spaces. J. Med. Chem. 2018, 61, 6546–6573.
67) Leenders, R.; Zijlmans, R.; van Bree, B.; van de Sande, M.; Trivarelli, F.; Damen, E.; Wegert, A.; Müller, D.; Ehler, J. E.; Feger, D.; Heidemann-Dinger, C.; Kubbutat, M.; Schächtele, C.; Lenstra, D. C.; Mecinović, J.; Müller, G. Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2. Bioorg. Med. Chem. Lett. 2019, 29, 2516–2524.
68) Aronov, A. M.; Goldman, B. B. A model for identifying HERG K+ channel blockers. Bioorg. Med. Chem. 2004, 12, 2307–2315.
69) Aronov, A. M. Predictive in silico modeling for hERG channel blockers. Drug Discov. Today 2005, 10, 149–155.
70) Fang, Z.; Song, Y.; Zhan, P.; Zhang, Q.; Liu, X. Conformational restriction: an effective tactic in 'follow-on'-based drug discovery. Future Med. Chem. 2014, 6, 885–901.
71) Chen, A.; Aspiotis, R.; Campeau, L. C.; Cauchon, E.; Chefson, A.; Ducharme, Y.; Falgueyret, J. P.; Gagné, S.; Han, Y.; Houle, R.; Laliberté, S.; Larouche, G.; Lévesque, J. F.; McKay, D.; Percival, D. Renin inhibitors for the treatment of hypertension: Design and optimization of a novel series of spirocyclic piperidines. Bioorg. Med. Chem. Lett. 2011, 21, 7399–7404.
72) Lee, Y. T.; Vasconcellos, J. F.; Yuan, J.; Byrnes, C.; Noh, S. J.; Meier, E. R.; Kim, K. S.; Rabel, A.; Kaushal, M.; Muljo, S. A.; Miller, J. L. LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo. Blood 2013, 122, 1034–1041.
73) Teng, W. C.; Oh, J. W.; New, L. S.; Wahlin, M. D.; Nelson, S. D.; Ho, H. K.; Chan, E. C. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib. Mol. Pharmacol. 2010, 78, 693–703.
74) Vitaku, E.; Smith, D. T.; Njardarson, J. T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. J. Med. Chem. 2014, 57, 10257–10274.
75) Zaveri, N.; Jiang, F.; Olsen, C.; Polgar, W.; Toll, L. Novel α3β4 Nicotinic Acetylcholine Receptor-Selective Ligands. Discovery, Structure−activity studies, and pharmacological evaluation. J. Med. Chem. 2010, 53, 8187–8191.
76) Clement, H. A.; Hall, D. G. Synthesis of α-hydroxyalkyl dehydroazepanes via catalytic enantioselective borylative migration of an enol nonaflate. Tetrahedron Lett. 2018, 59, 4334– 4339.
77) Takahashi, K.; Ishiyama, T.; Miyaura, N. A borylcopper species generated from bis(pinacolato)diboron and its additions to α,β-unsaturated carbonyl compounds and terminal alkynes. J. Organomet. Chem. 2001, 625, 47–53.
78) Cheng, K. C.; Li, C.; Uss, A. S. Prediction of oral drug absorption in humans—from cultured cell lines and experimental animals. Expert Opin. Drug Metab. Toxicol. 2008, 4, 581–590.
79) Lavelle, D.; Saunthararajah, Y.; Vaitkus, K.; Singh, M.; Banzon, V.; Phiasivongsva, P.; Redkar, S.; Kanekal, S.; Bearss, D.; Shi, C.; Inloes, R.; DeSimone, J. S110, a Novel Decitabine Dinucleotide, Increases Fetal Hemoglobin Levels in Baboons (P. anubis). J. Transl. Med. 2010, 8, 92.
80) Sankaran, V. G.; Xu, J.; Ragoczy, T.; Ippolito, G. C.; Walkley, C. R.; Maika, S. D.; Fujiwara, Y.; Ito, M.; Groudine, M.; Bender, M. A.; Tucker, P. W.; Orkin, S. H. Developmental and Species-Divergent Globin Switching Are Driven by BCL11A. Nature 2009, 460, 1093–1097.
81) Lebensburger, J. D.; Pestina, T. I.; Ware, R. E.; Boyd, K. L.; Persons, D. A. Hydroxyurea Therapy Requires HbF Induction for Clinical Benefit in a Sickle Cell Mouse Model. Haematologica 2010, 95, 1599–1603.
82) Lavelle, D.; Molokie, R.; Ducksworth, J.; DeSimone, J. Effects of Hydroxurea, Stem Cell Factor, and Erythropoietin in Combination on Fetal Hemoglobin in the Baboon. Exp. Hematol. 2001, 29, 156–162.
83) Kundu, M. C.; Gore, L. R.; Maguire, S.; Gilmartin, A. G. Development and Characterization of a Model for Inducing Fetal Hemoglobin Production in Cynomolgus Macaques (Macaca fascicularis). Comp. Med. 2018, 68, 396–402.
84) Emmerson, C. J.; William, D. K. Preparation of substituted fused bi- or tri- heterocyclic compounds as EHMT2 inhibitors. WO2018064557, Apr. 5, 2018.
85) Quinn, J. F.; Razzano, D. A.; Golden, K. C.; Gregg, B. T. 1,4 -Cyclohexadiene with Pd/C as a rapid, safe transfer hydrogenation system with microwave heating. Tetrahedron Lett. 2008, 49, 6137−6140.
86) Lavelle, D.; Chin, J.; Vaitkus, K.; Redkar, S.; Phiasivongsa, P.; Tang, C.; Will, R.; Hankewych, M.; Roxas, B.; Singh, M.; Saunthararajah, Y.; DeSimone, J. Oral decitabine reactivates expression of the methylated γ-globin gene in papio anubis. Am. J. Hematol. 2007, 82, 981−985.
87) Akpan, I.; Banzon, V.; Ibanez, V.; Vaitkus, K.; DeSimone, J.; Lavelle, D. Decitabine increases fetal hemoglobin in papio anubis by increasing gamma-globin gene transcription. Exp. Hematol. 2010, 38, 989−993.
88) Rivers, A.; Vaitkus, K.; Ibanez, V.; Ruiz, M. A.; Jagadeeswaran, R.; Saunthararajah, Y.; Cui, S.; Engel, J. D.; DeSimone, J.; Lavelle, D. The LSD1 inhibitor RN -1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis). Haemotologicia 2016, 101, 688−697.
89) Shinozuka, T.; Tsukada, T.; Fujii, K.; Tokumaru, E.; Matsui, Y.; Wakimoto, S.; Ogata, T.; Araki, K.; Sawamura, R.; Watanabe, N.; Mori, M.; Tanaka, J. Structure−activity relationship studies of 3- or 4-pyridine derivatives of DS-6930. ACS Med. Chem. Lett. 2019, 10, 358−362.
90) Watanabe, A.; Nakamura, K.; Okudaira, N.; Okazaki, O.; Sudo, K.; Risk assessment for drug - drug interaction caused by metabolismbased inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab. Dispos. 2007, 35, 1232−1238.
91) Arita, T.; Asano, M.; Kubota, K.; Domon, Y.; Machinaga, N.; Shimada, K. Discovery of DS34942424: An orally potent analgesic without mu opioid receptor agonist activity. Bioorg. Med. Chem. Lett. 2020, 28, 115714.
92) Winn, M. D. et al. Overview of the CCP4 Suite and Current Developments. Acta. Cryst. 2011, D67, 235–242.
93) Battye, T.G.; Kontogiannis, L.; Johnson, O.; Powell, H. R.; Leslie, A.G.W. IMosflm: a new graphical interface for diffraction-image processing with MOSFLM. Acta Cryst. 2011, D67, 271–281.
94) Murshudov, G. N. et al. REFMAC5 for the Refinement of Macromolecular Crystal Structures. Acta. Cryst. 2011, D67, 355–367.
95) Emsley, P.; Cowtan, K. Coot: Model-Building Tools for Molecular Graphics. Acta. Cryst. 2004, D60, 2126–2132.
論文の公開元へ
